Regenerative Medicines for Alzheimers Disease - A Pipeline Analysis Report

Overview of the drug development for regenerative medicines for Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disorder responsible for about 60-80% of dementias. It affects the cognitive functions to the extent that the patients find it difficult to perform day-to-day tasks. It results in a progressive decline in cognition. One of the key known causes of Alzheimer’s disease is the overexpression of the tau protein, which leads to its accumulation in the neurons, causing neurofibrillary tangles. The tau accumulation interferes with the signaling pathway of the neurons, which causes difficulty with the cognitive functions. Amyloid-beta is another protein that is believed to play a role in the development of Alzheimer’s disease. The average life span of a patient with Alzheimer’s disease is eight years after the symptoms become noticeable. In 2014, about 24 million people around the world have dementia, which makes 14.4 million to 19.2 million cases of Alzheimer’s diseases. The number of dementia patients is expected to quadruple by 2050 worldwide, in turn, promoting the drug development for regenerative medicines for Alzheimer’s disease. The US has the highest prevalence rate followed by Western European countries, Latin American countries, and China.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for the treatment of Alzheimer’s disease. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of Alzheimer’s disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• CHA Biotech
• Celltex Therapeutics
• Johnson & Johnson
• Sangamo Therapeutics
• Voyager Therapaeutics

Therapeutic assessment of the drug development pipeline for regenerative medicines for Alzheimer’s disease by route of administration

• Intravenous
• Intracerebral

The intravenous route of administration (ROA) involves the application of the drug directly into the veins, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for regenerative medicines for Alzheimer’s disease by therapy

• Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development for regenerative medicines for Alzheimer’s disease are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for regenerative medicines for Alzheimer’s disease?
• What are the companies that are currently involved in the drug development for regenerative medicines for Alzheimer’s disease?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.